Factors Favoring Long Term Survival in Patients with Stage IV Epithelial Ovarian Cancer: An Institutional Research (original) (raw)
Related papers
International Journal of Hematology and Oncology, 2017
The aim if this study is to explore the impact of the various prognostic factors on overall survival in women with ovarian cancer (OC). Patients diagnosed with gynecologic malignancy in Gynecology Clinic of Baskent University Medicine Faculty between 2010 and 2015 included to study. Patients with ovarian (n= 112) cancers examined retrospectively. Kaplan-Meier, Univariate and Multivariate Cox regression model were performed to estimate for associations of potential variables with survival factors. The mean patient age was 56.4 y, range 20-80. The overall survival was 94.3%, 83.4%, 66.4%, 54.7% and 42.8% at 1, 2 3, 4 and 5 years respectively (60.5 months, range 43-68). 3-year disease-free survival was 25.3% (18.3 months, range 17-20). Multivariate analysis of patients indicated that stage, histology, grade, age at diagnosis, comorbidity, recurrence, BMI, menopausal status and regional distance were independent prognostic factors on survival (p< 0.05). In conclusion, these results will presents a framework to identify fundamental causes in survival for OC.
2022
Objectives: To assess survival and prognostic factors among women with epithelial ovarian cancer in Western Saudi Arabia. Methods: A retrospective cohort study was carried out between October 2000 and May 2018, reviewing clinical and pathology data of all women who underwent staging or debulking surgery for epithelial ovarian cancer. Analysis of disease-free survival (DFS), overall survivals (OS) and the associated factors used Kaplan-Meier method in addition to cox multivariate regression. Results: A total of 144 patients were included (median age=49.5 years), with a median follow-up time was Original Article 3.4 years. Majority (59.7%) of the patients were diagnosed at an advanced stage (III or IV). The mean (95% CI) DFS was 82.3 (67.8-96.8) months, OS was 96.2 (81.3-111.2) months, and the 5-year survival rate was estimated as 38.9%. Univariate analysis showed that older age, clear cell or papillary carcinoma subtypes, serous type, advanced International Federation of Gynecology and Obstetrics (FIGO) stage and the presence of residual disease were associated with poorer DFS and OS (log rank <0.05). Cox regression showed FIGO stage and residual disease >1cm as the strongest prognostic factors independently associated with DFS and OS. Conclusion: Improving early diagnosis and achieving optimal cytoreduction are the most critical challenges to achieve significant positive impact on survival of women with epithelial ovarian cancer.
Treatment Outcomes of Epithelial Ovarian Cancer A Longitudinal Study
Asian Pacific Journal of Cancer Care
Objective: To evaluate the treatment outcomes in patients with epithelial ovarian cancer following neoadjuvant chemotherapy presenting at a tertiary care hospital. Materials and methods: It was a longitudinal study conducted at the department of medical oncology, Jinnah postgraduate medical center, Karachi Pakistan from May 2018-Feb 2020. One twenty-five women of age 20-80 years with confirmed diagnosis of ovarian carcinoma (stage 1-4) who were referred from different medical institutes of Karachi were included in the study. Surgery and systematic chemotherapy were the primary treatment at the time of ovarian cancer diagnosis. Until death or last follow-up, treatment results were measured. Based on the treatments received from recurrence, systematic chemotherapy was further classified as 2nd line and 3rd line. Females who relapse after 6 months with platinum based treatment were underwent for re-treatment with carboplatin and cisplatin in combination or alone or those who recurred w...
British journal of cancer, 1990
The data on 914 patients enrolled in four randomised trials in advanced ovarian cancer, consecutively conducted by the same cooperative group between 1978 and 1986, were analysed with the aims of: (1) determining the impact of selected prognostic variables on survival; (2) finding, from the interaction of favourable prognostic factors and treatment, an approximate estimate of the magnitude of the survival advantage associated with the use of platinum-based combination chemotherapy. The overall 3-year survival in this series of patients is twice that reported historically (22%; 95% CL 18.7-25.4). The proportional hazard regression model was used to perform the analysis on survival. Residual tumour size, age, FIGO stage and cell type were all independent determinants of survival. Differences in survival from the various prognostic groups were impressive with 5-year survival rates ranging from 7 to 62%. However, these differences were not qualitative (i.e. the kinetics of survival were...
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2017
PURPOSE To evaluate the potential influence of clinical characteristics on survival of patients with advanced-stage of ovarian malignancies. METHODS The study included 163 women with FIGO stages 3 and 4 ovarian malignancies. Detailed history (family history of malignancies, age, menopausal status, body mass index (BMI), parity, comorbidities, symptoms/signs) was taken from all patients including tumor histopathological findings. Patients were postoperatively followed up to 5 years and adverse events were recorded. Univariate and multivariate survival analyses were applied. RESULTS Patient median survival was 22.77 months (range 1-91). Almost 74% of women survived in the first postoperative year, but only 12.9% had 5-year survival. In the postoperative period, each additional 6 months presented significant risk for unfavorable outcome. Women who were menopausal (p=0.033) and especially if older than 65 years (p=0.016) had worse prognosis. Patients with BMI ≤25 kg/m2 had significantly...
Introduction: Ovarian cancer is the second most common malignancy in women, the most common cause of gynecologic cancer deaths, and most patients have advanced stage disease at the time of diagnosis. The purpose of this study was to estimate the 5-year survival of patients with epithelial ovarian cancer based on age, tumor histology, stage of disease, and type of treatment. Methods: This study was conducted on 120 patients with epithelial ovarian cancer referred to Shahid Sadoughi hospital and Shah Vali oncology clinic of Yazd from 2006 to 2012. Demographic data and patient records were studied to evaluate the treatment outcome, pathology of the tumor, and stage of disease. Finally, the overall survival rate and tumor-free survival of patients was assessed. Results: The mean patient age was 53.87± 14.11 years. Most participants had stage I (36.7%) or stage II (35%) disease. Serous adenocarcinoma (57.6%) was the most common pathology found in patients with epithelial ovarian cancer. The overall survival of patients in this study was significantly associated with the histological tumor type (p = 0.000) and disease stage (p = 0.0377). Stage I (84.18%) and serous adenocarcinoma (72.81%) demonstrated the best survival. The tumor-free survival rates were not associated with histology types (p = 0.079), surgical procedure (p = 0.18), or chemotherapy (p = 0.18). Conclusion: The survival of patients with epithelial ovarian cancer was significantly associated with disease stage. Serous adenocarcinoma also had the best prognosis among the pathologies studied. Therefore, early detection of ovarian cancer can substantially increase the survival rate.
JCO Global Oncology, 2021
PURPOSE This study was designed to investigate the clinicopathologic predictors of progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC) following primary treatment in Lagos, Nigeria. MATERIALS AND METHODS Using data from a retrospective cohort of 126 patients who received treatment for EOC between 2010 and 2018, we identified 83 patients with a complete clinical record for subsequent data analysis. Patients' demographics and updated 2-year follow-up status were abstracted from medical records. Kaplan-Meier survival curves were compared using the log-rank test, and Cox proportional hazard models were used for multivariate analysis to identify independent predictors of survivals following treatment in EOC patients. RESULTS The median PFS and OS were 12 and 24 months, respectively. After adjusting for covariates in the multivariate analysis, younger age ≤ 55 years (hazard ratio [HR] = 0.40; 95% CI, 0.22 to 0.74; P = .01) and Int...
PROGNOSTIC FACTORS IN EPITHELIAL OVARIAN CARCINOMA: A REFERENCE INSTITUTION EXPERIENCE
Journal of Turkish Society …, 2011
Aim: To evaluate epidemiologic and prognostic factors of the patients with epithelial ovarian cancer retrospectively and to investigate the factors that effect overall survival. Material and methods: Between January 1990 and December 2004, 149 patients with malign epithelial ovarian tumor were included to this study. Age, parity, primary complaint and postoperative histopathology, surgical stage and maximal diameter of residual tumor of the patients were obtained and factors that effect overall survival were evaluated. Results: Mean age of the patients was 52.8 ± 13 years. Most of the patients were multipar (85.9%) and most fruquent (n: 88) (59.1%) complaint was abdominal swelling. Postoperative surgical stages were stage I in 24 (16.1%), stage II in11 (7.4%), stage III in 87 (58.4%) and stage IV in 27 (18.1%) patients. Maximal diameter of residual tumor was <1 cm in 68 patients (45.6%), ≥1 cm in 57 patients (38.3%) while there was no residual tumor in 24 patients (16.1%). Histopathologic cell types distributed as: serous (53.6%), endometrioid (16.7%), musinous (10.7%), clear cell (10.7%), others (7.8%). The patinets <65 years old had similar overall survival compared to those who were ≥65 years old (p>0.05). The mean overall survival of the patients with maximal residual tumor size ≤1 cm, >1cm and no residual tumor were obtained to be 54.8 months, 22.7 months and 43.5 months respectively (p<0.001). According to the surgical stages I,II,III and IV mean survival was 78.5 months, 60.1 months, 33.9 months and 16.1 months respectively and significantly different (p<0.001). Conclusion: The data of the study revealed that surgical stage and postoperative maximum residual tumor diameter had significantly effect on overall survival where it was not effected by the age of the patients in epitelial ovarian cancers. So, early diagnosis and optimal cytoreduction should be attemped to improve the prognosis of the patients.
Cancer, 2008
BACKGROUND. The purpose was to identify the factors predictive of recurrence and survival in patients with high-risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy. METHODS. Data was extracted from patients who underwent primary surgery followed by adjuvant therapy in 2 randomized trials by the Gynecologic Oncology Group (Protocols 95 and 157). Kaplan-Meier survival estimates and Cox proportional hazards model adjusted for covariates were used for analyses. RESULTS. Of 506 patients (median age 5 56.2 years), 347 (68.6%) had stage I and 159 (31.4%) had stage II cancers. The 5-year recurrence-free (RFS) and overall survivals (OS) were 75.5% and 81.7%, respectively. On multivariate analysis, older age, higher stage, higher grade, and malignant cytology were independent prognostic factors predictive for recurrence and poorer survival. The risk of recurrence was higher for those !60 versus < 60 years (hazards ratio [HR] 5 1.57, 95% confidence interval [CI], 1.12-2.19), stage II (stage II: HR 5 2.70, 95% CI, 1.41-5.16) versus stage IA or IB, grade 2 (HR 5 1.84, 95% CI, 1.04-3.27) and grade 3 (HR 5 2.47, 95% CI, 1.39-4.37) versus grade 1, and positive versus negative cytology (HR 5 1.72, 95% CI, 1.21-2.45). By using these factors in a prognostic index, those with lowrisk (no or 1 risk factor), intermediate-risk (2 factors), and high-risk (3-4 risk factors) disease had survivals of 88%, 82%, and 75%, respectively (P < .05). CONCLUSIONS. Age, stage, grade, and cytology are important prognostic factors in highrisk early-stage epithelial ovarian cancer. This information may be used in the design of future clinical trials.
Prognostic Significance of Residual Disease in Patients with Stage IV Epithelial Ovarian Cancer
Gynecologic Oncology, 1997
To evaluate the role of surgical debulking in patients with stage IV ovarian cancer. We conducted a retrospective review of patients with advanced epithelial ovarian cancer treated at M. D. Anderson Cancer Center. Eligible patients included women with stage IV disease treated with platinum-based chemotherapy. Surgical debulking was considered optimal if the diameter of the largest residual tumor was 2 cm or less. Survival analysis and comparisons were performed using the Kaplan-Meier method and the log-rank test. One hundred eight women with stage IV ovarian cancer were identified. The extraperitoneal metastatic sites were the liver parenchyma in 16 patients, the pleura in 54 patients, a variety of other organs in 22, and two or more sites in the remaining 16. Median age of the patient population was 58 years (range 35-81 years). Surgery to reduce the primary tumor was performed in 100 patients. The procedures included salpingo-oophorectomy with or without hysterectomy in 94 patients, omentectomy in 90, small bowel resection in 4, large bowel resection in 23, and splenectomy in 2. At the completion of surgery, tumor reduction was considered optimal in 31 patients, suboptimal in 61, and undetermined in 8. The overall median survival for optimally debulked patients was 25 months compared to 15 months for suboptimally debulked patients (P < 0.02). The progression-free survival, on the other hand, was not statistically different between the two groups. Residual tumor seems to be an important prognostic factor in patients with stage IV ovarian cancer. Surgical debulking may play a significant role in the treatment of these patients.